Help | RSS Feed



Alnylam Pharmaceuticals, Inc. (NASD:ALNY) Seasonal Chart

Seasonal Chart Analysis

Analysis of the Alnylam Pharmaceuticals, Inc. (NASD:ALNY) seasonal charts above shows that a Buy Date of October 21 and a Sell Date of January 15 has resulted in a geometric average return of 11.5% above the benchmark rate of the S&P 500 Total Return Index over the past 15 years. This seasonal timeframe has shown positive results compared to the benchmark in 13 of those periods. This is a very good rate of success and the return outperforms the relative buy-and-hold performance of the stock over the past 15 years by an average of 1.51% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran (Onpattro) for amyloidosis and givosiran (Givlaari) for acute hepatic porphyria (AHP), Alnylam has several partnered several pipeline candidates in rare genetic diseases, liver diseases, and other indications as well. Up-front fees from research partnerships with firms such as Regeneron, Sanofi, and The Medicines Company have boosted Alnylam’s cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

To download ALNY seasonal chart data, please log in or Subscribe.

 

Stocks mentioned in this post:

    Search Seasonal Charts by Symbol, Company, or Term

   Symbols by Letter: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z


Sponsored By...
Seasonal Advantage Portfolio by CastleMoore